The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ampio Pharmaceuticals has an asset utilization ratio of 2.31 percent. This indicates that the company is making $0.0231 for each dollar of assets. An increasing asset utilization means that Ampio Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Ampio Pharm
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Ampio Pharm, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Ampio Pharm based on Ampio Pharm hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Ampio Pharm's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Ampio Pharm's related companies.
Watch out for price decline
Please consider monitoring Ampio Pharm on a daily basis if you are holding a position in it. Ampio Pharm is trading at a penny-stock level, and the possibility of delisting is much higher compared to other pink sheets. However, just because the pink sheet is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Ampio Pharm stock to be traded above the $1 level to remain listed. If Ampio Pharm pink sheet price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Ampio expected Price
Ampio Pharm technical pink sheet analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, pink sheet market cycles, or different charting patterns.
A focus of Ampio Pharm technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Ampio Pharm trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Going after Ampio Financials
This firm reported the previous year's revenue of 1.16
M. Net Loss for the year was (12.3
M) with profit before overhead, payroll, taxes, and interest of 458.96
K.
| 2010 | 2012 | 2019 | 2020 (projected) |
Revenues USD | 18.75 K | 50 K | 57.5 K | 53.18 K | Revenues | 18.75 K | 50 K | 57.5 K | 53.18 K |
Deferred Revenue Breakdown
Ampio Pharmaceuticals Deferred Revenue is increasing over the years with slightly volatile fluctuation. Deferred Revenue is expected to dwindle to about 603.1
K. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Ampio Pharmaceuticals Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 637,632
| 2010 | 481,250 |
| 2012 | 431,250 |
| 2013 | 381,250 |
| 2014 | 554,463 |
| 2019 | 637,632 |
| 2020 | 603,100 |
Can Ampio Pharmaceuticals build up on the latest surge?
The downside variance is down to 22.84 as of today. Ampio Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Ampio Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Ampio Pharmaceuticals volatility.
Our Final Take On Ampio Pharmaceuticals
Although other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Ampio Pharmaceuticals may offer a potential longer-term growth to shareholders. While some shareholders may not share our view, we believe it may be a good time to increase your existing holdings in Ampio. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Ampio Pharmaceuticals.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Ampio Pharm. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
